Cetaphil Celebrates 75 Years of Sensitive Skincare Leadership

Cetaphil marks its 75th anniversary this month by announcing a commitment to keeping consumers with sensitive skin as the core focus through ongoing innovation and improving inclusivity within dermatology.

 

“For 75 years, our sole focus has been to use science to understand and treat the unique needs of sensitive skin,” said Lisa Morris, general manager of the consumer business US. “Throughout our history and as we look to the future, we will continue to push the boundaries of innovation and research to bring our absolute best to our consumers. We'll continue to prioritize initiatives that transform the way sensitive skin is portrayed, understood, and treated.”

 

A flagship brand in the Galderma portfolio, Cetaphil has several new initiatives that will help shape the conversation around and knowledge of, sensitive skin worldwide as the brand looks to the future.

 

To mark the occasion, Cetaphil's complete brand restage is culminating in the debut of a new campaign, We Do Skin. You Do You. Research shows that many consumers think twice before, or entirely avoid, partaking in daily activities they enjoy out of fear that their skin will react or flare up. Cetaphil's new campaign was created to empower people with sensitive skin to do more of the things they love without hesitation.

Over the past seven decades, Cetaphil's portfolio has evolved to address a variety of complex sensitive skin needs, featuring dermatologist-backed cleansers and moisturizers that are specifically formulated to defend against the five signs of skin sensitivity. Innovation remains core to the brand with the development of 12 new products in 2022. In particular, the brand offers a Hydrating Foaming Cream Cleanser, Deep Hydration Skin Restoring Water Gel, and a regimen developed for those suffering from the itch-scratch cycle of eczema. Accepted by the National Eczema Association, the Cetaphil Eczema Restoraderm line features three products to help relieve irritation and nourish the skin while hydrating and repairing the skin's moisture barrier.

Structures within healthcare facilities, academic institutions and society at large have resulted in inequities in dermatologic care. Through several initiatives, Cetaphil is committed to establishing a movement aimed at increasing academic, professional and cultural competency within dermatology to eliminate persistent knowledge gaps in treating all sensitive skin. In phase one, this includes academic training and clinical trials. 
 

Cetaphil is supporting the distribution of The Full Spectrum of Dermatology: A Diverse and Inclusive Atlas, Volume 2. This comprehensive resource helps physicians recognize the clinical presentations of skin diseases on all skin tones. Led by co-authors Drs. Misty Eleryan and Adam Friedman, the Atlas provides high resolution, side-by-side images of the most common dermatology conditions in a full spectrum of skin tones so that dermatologists are equipped to diagnose and treat all skin.

 

While Cetaphil has been working to improve representation in its clinical trials, work on the matter remains. Cetaphil aims to establish a new standard in clinical skincare testing to shift the dynamic of the entire industry. To ensure skincare testing is more representative of diverse skin tones, Cetaphil plans to increase skin of color participants in its clinical trials from 26% to roughly 40% by 2024.

 

To learn more about the brand's newest offerings and commitment to providing complete care for sensitive skin, visit Cetaphil.com.